Trimetazidine

Jump to navigation Jump to search
Trimetazidine
Clinical data
Routes of
administration
Orally
ATC code
Pharmacokinetic data
ExcretionMainly via kidney (unchanged)
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC14H22N2O3
Molar mass266.336 g/mol
3D model (JSmol)

WikiDoc Resources for Trimetazidine

Articles

Most recent articles on Trimetazidine

Most cited articles on Trimetazidine

Review articles on Trimetazidine

Articles on Trimetazidine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Trimetazidine

Images of Trimetazidine

Photos of Trimetazidine

Podcasts & MP3s on Trimetazidine

Videos on Trimetazidine

Evidence Based Medicine

Cochrane Collaboration on Trimetazidine

Bandolier on Trimetazidine

TRIP on Trimetazidine

Clinical Trials

Ongoing Trials on Trimetazidine at Clinical Trials.gov

Trial results on Trimetazidine

Clinical Trials on Trimetazidine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Trimetazidine

NICE Guidance on Trimetazidine

NHS PRODIGY Guidance

FDA on Trimetazidine

CDC on Trimetazidine

Books

Books on Trimetazidine

News

Trimetazidine in the news

Be alerted to news on Trimetazidine

News trends on Trimetazidine

Commentary

Blogs on Trimetazidine

Definitions

Definitions of Trimetazidine

Patient Resources / Community

Patient resources on Trimetazidine

Discussion groups on Trimetazidine

Patient Handouts on Trimetazidine

Directions to Hospitals Treating Trimetazidine

Risk calculators and risk factors for Trimetazidine

Healthcare Provider Resources

Symptoms of Trimetazidine

Causes & Risk Factors for Trimetazidine

Diagnostic studies for Trimetazidine

Treatment of Trimetazidine

Continuing Medical Education (CME)

CME Programs on Trimetazidine

International

Trimetazidine en Espanol

Trimetazidine en Francais

Business

Trimetazidine in the Marketplace

Patents on Trimetazidine

Experimental / Informatics

List of terms related to Trimetazidine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Trimetazidine is a drug for angina pectoris sometimes referred to by the brand name Vastarel MR. Each tablet contains 35 mg of trimetazidine. Trimetazidine is an anti-ischemic (anti-anginal) metabolic agent, that improves myocardial glucose utilization through inhibition of Fatty acid metabolism.

By preserving the energy metabolism in cells exposed to hypoxia or ischemia, trimetazidine prevents a decrease in intracellular adenosine triphosphate levels, thereby ensuring the proper functioning of ionic pumps and transmembranous sodium-potassium flow whilst maintaining cellular homeostasis.

The drug also inhibit b oxidation of fatty acid in blood vessles

Controlled studies in angina patients have shown that trimetazidine increases coronary flow reserve, thereby delaying the onset of ischemia associated with exercise, limits rapid swings in blood pressure without any significant variations in heart rate, significantly decreases the frequency of angina attacks, and leads to a significant decrease in the use of nitrates.

It improves left ventricular function in diabetic patients with coronary artery disease. Recently, it has been shown to be effective in patients with heart failure of different etiologies.

It is described as the first cytoprotective anti-ischemic agent, acts by directly counteracting all the major metabolic disorders occurring within the ischemic cell. The actions of trimetazidine include limitation of intracellular acidosis, correction of disturbances of transmembrane ion exchanges, and prevention of excessive production of free radicals.

It is usually prescribed as a long-term treatment of angina pectoris, and in some countries (including France) for tinnitus and dizziness.

Interactions

Vastarel MR has high safety and tolerability profile.

Q. Can i use sildenafil(viagra) while taking Vastarel MR?

A. Go on, unlike nitrates, Vastarel MR with sildenafil is fully safe (allowed).

Vastarel MR is very safe (no drug-drug interactions)

Dosage and Administration

Vastarel MR tablets is taken twice daily, providing 24-hr cardioprotection.

World Wide

Vastarel MR is also distributed as: Vastarel 35 mg, Vastarel 20 mg, Vastarel LM, Vastarel LP, Preductal MR, Flavedon MR and Trizedon MR.

References

1. Sellier P, Broustet JP. Am J Cardiovasc Drugs. 2003;3:361-369. 2. Génissel P, Chodjania Y, Demolis JL, Ragueneau I, Jaillon P. Eur J Drug Metab Pharmacokinet. 2004;29: 61-68. 3. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. Circ Res. 2000;86:580-588. 4. Stanley WC, Marzilli M. Trimetazidine for the treatment of stable angina: biochemical mechanisms and clinical efficacy. Fundamental Clin Pharmacol. 17:133–145, 2003.

External links